John Bridgewater
Impact in
Papers in
- Co-authors
- Juan W. Valle (67 shared papers)Harpreet Wasan (48 shared papers)Josep Tabernero (19 shared papers)David Cunningham (35 shared papers)Thierry André (3 shared papers)Tamas Hickish (5 shared papers)C. Boni (2 shared papers)Philip R. Clingan (2 shared papers)
- Journals
- Journal of Clinical Oncology (75 papers)Annals of Oncology (49 papers)BMC Cancer (9 papers)British Journal of Cancer (9 papers)European Journal of Cancer (8 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
John Bridgewater
241 papers receiving 16.9k citations
John Bridgewater's Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 8.1k
- Surgery 7.9k
- Hepatology 1.1k
- Pulmonary and Respiratory Medicine 3.7k
- Pathology and Forensic Medicine 1.7k
Countries citing papers authored by John Bridgewater
This map shows the geographic impact of John Bridgewater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Bridgewater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Bridgewater more than expected).
Fields of papers citing papers by John Bridgewater
This network shows the impact of papers produced by John Bridgewater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Bridgewater. The network helps show where John Bridgewater may publish in the future.
Co-authors
The 25 scholars most cited alongside John Bridgewater, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 252 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Hit paper breakdown → | 2010 | 3121 |
| 2 | Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer Hit paper breakdown → | 2004 | 2800 |
| 3 | Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial Hit paper breakdown → | 2009 | 1662 |
| 4 | Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma Hit paper breakdown → | 2014 | 1099 |
| 5 | 2009 | 435 | |
| 6 | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2013 | 419 |
| 7 | Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 313 |
| 8 | Systemic therapies for intrahepatic cholangiocarcinoma Hit paper breakdown → | 2020 | 281 |
| 9 | Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial Hit paper breakdown → | 2013 | 281 |
| 10 | 2013 | 278 | |
| 11 | 2013 | 259 | |
| 12 | 2014 | 234 | |
| 13 | 2015 | 209 | |
| 14 | 2009 | 208 | |
| 15 | 2014 | 197 | |
| 16 | 2014 | 193 | |
| 17 | Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study Hit paper breakdown → | 2021 | 178 |
| 18 | 1995 | 172 | |
| 19 | 2016 | 157 | |
| 20 | 2019 | 156 |
About John Bridgewater
John Bridgewater is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 252 papers that have together received 17.2k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (103 papers), Colorectal Cancer Treatments and Studies (63 papers), Pancreatic and Hepatic Oncology Research (35 papers), Gastric Cancer Management and Outcomes (32 papers), Cancer Genomics and Diagnostics (24 papers), Lung Cancer Treatments and Mutations (22 papers), Fibroblast Growth Factor Research (20 papers) and Gallbladder and Bile Duct Disorders (20 papers). The work is most often cited by research in Oncology (8.1k citations), Surgery (7.9k citations), Hepatology (1.1k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Pathology and Forensic Medicine (1.7k citations). John Bridgewater has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Juan W. Valle, Harpreet Wasan, Josep Tabernero, David Cunningham, Thierry André, Tamas Hickish, C. Boni, Philip R. Clingan, Matilde Navarro and Aimery de Gramont. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, BMC Cancer, British Journal of Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.